Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Maeda, T.
Right arrow Articles by Harada, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maeda, T.
Right arrow Articles by Harada, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology 30:534-541 (2000)
© 2000 Foundation for Promotion of Cancer Research

Prognostic Factors in Advanced Non-small Cell Lung Cancer: Elevated Serum Levels of Neuron Specific Enolase Indicate Poor Prognosis

Tadashi Maeda, Hiroshi Ueoka, Masahiro Tabata, Katsuyuki Kiura, Takuo Shibayama, Kenichi Gemba, Nagio Takigawa, Akio Hiraki, Hideki Katayama and Mine Harada+,§

Department of Internal Medicine II, Okayama University Medical School, Okayama, Japan

Background: Non-small cell lung cancer (NSCLC) is resistant to chemotherapy and prognosis of advanced NSCLC patients is considered to be dependent on various prognostic factors.

Methods: We analyzed prognostic factors in patients with advanced NSCLC who had been enrolled in clinical trials conducted by the Okayama Lung Cancer Study Group between 1978 and 1992 using two kinds of multivariate analysis, Cox’s multivariate analysis and recursive partitioning and amalgamation (RPA) analysis.

Results: The first analysis was performed on 261 patients using 28 variables. Performance status (PS), clinical stage, liver metastasis or serum albumin level was an independent prognostic factor by Cox’s analysis. In the second analysis performed on 128 patients having data on neuron specific enolase (NSE), NSE was the most important prognostic factor. Using the RPA method, three subgroups with significantly different survival potentials were defined. Among them, patients with normal serum NSE levels and good PS were found to obtain a markedly favorable prognosis [median survival time (MST) 22.1 months, 3-year survival rate 42.9%], whereas the survival of patients with elevated serum NSE levels and bone metastasis was extremely short (MST 4.7 months, 3-year survival rate 0%).

Conclusions: These results indicate that analysis of prognostic factors including serum levels of NSE is useful for predicting the survival of patients with advanced NSCLC.

+ For reprints and all correspondence: Hiroshi Ueoka, Department of Medicine II, Okayama University Medical School, 2–5–1 Shikatacho Okayama 700-8558, Japan. E-mail: hueoka@hospital.okayama-u.ac.jp

§ Abbreviations: NSCLC, non-small cell lung cancer; RPA, recursive partitioning and amalgamation; PS, performance status; NSE, neuron specific enolase; MST, median survival time


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.